Compugen's Q2 2025: Contradictions Uncovered in COM701 Trial Progress and Market Potential

Immunotherapy and Pipeline Advancement:
- Compugen reported progress in its immuno-oncology clinical and early-stage pipeline programs, with the first patient dosed in its MAIA-ovarian trial and progress in opening sites in the US and Israel.
- This advancement is driven by the company's focus on novel mechanisms of action and innovative combinations in immuno-oncology.

Financial Stability and Cash Runway:
- Compugen ended Q2 2025 with approximately $93.9 million in cash, with a cash runway expected into 2027.
- The solid balance sheet is attributed to milestones and royalties from AstraZeneca and Gilead, which support the advancement of its pipeline and operations.

TIGIT and Partnership Opportunities:
- Compugen highlighted its partnership with AstraZeneca on rilvegostomig, an Fc-reduced anti-PD-1 TIGIT bispecific, with potential peak year revenues of over $5 billion.
- AstraZeneca's broad development strategy for rilvegostomig, combined with Compugen's Fc inactive clinical-stage TIGIT antibody, COM902, presents strategic opportunities for the company.

COM701 and Ovarian Cancer Opportunity:
- The company is dosing patients in its MAIA-ovarian trial, which aims to demonstrate the potential advantage of COM701 in terms of durability of response and tolerability in the platinum-sensitive ovarian cancer setting.
- This trial is seen as a key opportunity to address an unmet medical need in this patient population, potentially supporting a broader clinical development program.